Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III lung cancer that involves certain lymph nodes (N2) but is planned to be surgically removable
- Your lung cancer is a non-squamous type and has been confirmed on biopsy or cell tests
- Your cancer has an EGFR mutation: either Ex19del or L858R (or with these along with other EGFR changes)
- You can likely have full surgery: your surgical team must agree it can be completely removed
- Your general health score (ECOG) is 0 or 1, and your health has not noticeably worsened in the last 2 weeks
- You have not had prior lung-cancer treatments like chemotherapy, EGFR pills, immunotherapy, or other study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.